Wells Fargo Maintains Overweight on AnaptysBio, Lowers Price Target to $40

BenzingaDec 12 14:16 ET · Ratings

AnaptysBio Price Target Cut to $36.00/Share From $90.00 by Guggenheim

Dow JonesDec 12 10:32 ET · Ratings

Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36

Moomoo NewsDec 12 08:31 ET · Ratings

Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40

Moomoo NewsDec 12 06:31 ET · Ratings

Buy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation Opportunity

TipRanksDec 12 06:05 ET · Ratings

AnaptysBio's Atopic Dermatitis Trial of BTLA Agonist Misses Endpoints

Yahoo FinanceDec 12 05:23 ET